Canada Pension Plan Investment Board acquired a new stake in NxStage Medical, Inc. (NASDAQ:NXTM) in the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 279,400 shares of the medical device company’s stock, valued at approximately $7,792,000. Canada Pension Plan Investment Board owned 0.43% of NxStage Medical as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also modified their holdings of NXTM. BlackRock Inc. grew its position in shares of NxStage Medical by 10.5% in the 2nd quarter. BlackRock Inc. now owns 5,289,606 shares of the medical device company’s stock valued at $147,581,000 after purchasing an additional 501,922 shares during the period. JPMorgan Chase & Co. boosted its position in NxStage Medical by 56.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,187,250 shares of the medical device company’s stock worth $33,113,000 after acquiring an additional 427,745 shares during the last quarter. SG Americas Securities LLC boosted its position in NxStage Medical by 2,037.2% during the 3rd quarter. SG Americas Securities LLC now owns 275,019 shares of the medical device company’s stock worth $7,670,000 after acquiring an additional 262,151 shares during the last quarter. Water Island Capital LLC boosted its position in NxStage Medical by 12.6% during the 2nd quarter. Water Island Capital LLC now owns 1,334,420 shares of the medical device company’s stock worth $37,230,000 after acquiring an additional 149,713 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec acquired a new position in NxStage Medical during the 2nd quarter worth approximately $3,962,000. Institutional investors and hedge funds own 83.58% of the company’s stock.
A number of equities analysts have weighed in on NXTM shares. BidaskClub downgraded NxStage Medical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 25th. Zacks Investment Research downgraded NxStage Medical from a “hold” rating to a “sell” rating in a research report on Saturday, August 11th. Finally, ValuEngine raised NxStage Medical from a “hold” rating to a “buy” rating in a research report on Friday, October 12th.
NASDAQ:NXTM opened at $28.86 on Friday. NxStage Medical, Inc. has a twelve month low of $22.70 and a twelve month high of $29.26. The company has a market cap of $1.90 billion, a price-to-earnings ratio of -131.18 and a beta of 0.05.
NxStage Medical (NASDAQ:NXTM) last released its quarterly earnings results on Wednesday, November 7th. The medical device company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. NxStage Medical had a negative return on equity of 2.50% and a negative net margin of 1.29%. The firm had revenue of $108.12 million during the quarter, compared to the consensus estimate of $108.07 million. Sell-side analysts expect that NxStage Medical, Inc. will post -0.02 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Canada Pension Plan Investment Board Takes $7.79 Million Position in NxStage Medical, Inc. (NXTM)” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/12/08/canada-pension-plan-investment-board-takes-7-79-million-position-in-nxstage-medical-inc-nxtm.html.
About NxStage Medical
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Featured Article: How Do Tariffs Affect Trade Balances?
Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.